U.S. FDA puts Merck's HIV drug trials on hold
Reuters
Published Dec 13, 2021 06:17PM ET
(Reuters) - Merck & Co said on Monday the U.S. Food and Drug Administration has placed clinical holds on trials testing the company's HIV drug islatravir.
The health regulator's move is based on observations of a drop in T-cell counts in some participants receiving the drug in clinical studies, the company said. T-cells are a critical component of the immune system that help the body fight infections.
The FDA has placed six studies related to islatravir on full clinical hold and seven on partial clinical hold.
Merck said it will stop dosing participants who are currently receiving the drug as part of the studies for preventing HIV, including oral and implant formulations, as well as injectable form of islatravir.
Gilead Sciences Inc (NASDAQ:GILD) and Merck said on Monday they have also decided to stop a mid-stage study evaluating islatravir in combination with Gilead's HIV treatment lenacapavir, after stopping dosing of participants in the same trial earlier in November.
Merck also paused enrollments in a late-stage trial testing islatravir this month.
No new studies related to the drug can be initiated while FDA's clinical holds are in place, Merck said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.